UBS downgraded Arcellx (ACLX) to Neutral from Buy with a price target of $115, up from $110, citing Gilead’s (GILD) acquisition of Arcellx for of $7.8B or $115 per share. The acquisition makes sense, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX: